Zynerba Pharmaceuticals, Inc. Price Today
Zynerba Pharmaceuticals, Inc.
ZYNE
Healthcare
$18.94M
💰
Market Cap
0
💸
Price to Earnings
$-0.8
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
3 |
Strong Buy |
4 |
Hold |
2 |
Sell |
0 |
Strong Sell |
0 |
ZYNE Price Forecast Target
0.4 👉 10.0 +2733%
ZYNE EPS Forecast
-0.8 👉 -0.6 +-25%
Financials
Profit Margin
0 %
Revenue Growth
0 %
Dividend
$ 0
Held Percent
6.1% - Insiders
12.1% - Institutions
81.8% - Public
Major Fund Holders
-
💰 Vanguard Group Inc $937,228.0
-
💰 Blackrock Inc. $360,641.0
-
💰 ETF Managers Group, LLC $310,954.0
-
💰 Renaissance Technologies, LLC $244,971.0
-
💰 Millennium Management Llc $196,230.0
Stock Ideas
Bill Gates Portfolio
With a portfolio valued at over $18 billion, the Bill & Melinda Gates Foundation Trust holds the endowment and funds the Bill & Melinda Gates Foundation. Bill and Melinda are the trustees for the Foundation Trust, and the endowment is managed by a t…
Jim Simons Portfolio
Jim Simons, the mastermind behind the Medallion Fund, has achieved such extraordinary returns that he has skyrocketed to the ranks of the world's wealthiest individuals. The secret to his success lies in the fund's implementation of high-frequency t…
Scott Ferguson Portfolio
With a strong background as a protégé of Bill Ackman, founder of Pershing Square Capital Management, Scott Ferguson has honed his skills and expertise in the art of activist investing. He possesses the ability to identify undervalued companies with …
Bruce Berkowitz Portfolio
Bruce Berkowitz, the esteemed founder of Fairholme, has established himself as a prominent figure in the investment world with his exceptional portfolio strategy. Since its inception in 1999, Fairholme has grown into a formidable $19 billion mutual …📮FAQ
Some Frequently Asked Questions.
The Zynerba Pharmaceuticals, Inc. industry is Drug Manufacturers—Specialty & Generic
The Zynerba Pharmaceuticals, Inc. sector is Healthcare
The Zynerba Pharmaceuticals, Inc. forecasted predicted Price to Earnings PE ratio is -0.6
The Zynerba Pharmaceuticals, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Zynerba Pharmaceuticals, Inc. is $18.94M
There are total of 46681585 float shares with 12.1% held by Institutions and 6.1% held by insiders
The MZynerba Pharmaceuticals, Inc. forecasted Earnings per Share EPS is $-0.6
The Zynerba Pharmaceuticals, Inc. Earnings per Share EPS is -0.8
The Zynerba Pharmaceuticals, Inc. company has $0 gross profits with 0 profit margins
The Zynerba Pharmaceuticals, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Zynerba Pharmaceuticals, Inc. Revenue is $0 with 0 revenue growth
The price target for Zynerba Pharmaceuticals, Inc. stock is $10.0 for the high target and $0.4 for the low target
The consensus analyst recommendations for Zynerba Pharmaceuticals, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Zynerba Pharmaceuticals, Inc. is Buy, with the following breakdown:
- Buy: 3
- Strong Buy: 4
- Hold: 2
- Sell: 0
- Strong Sell: 0
The Beta of Zynerba Pharmaceuticals, Inc. is 1.8
The dividend of Zynerba Pharmaceuticals, Inc. is $0
The dividend yield of Zynerba Pharmaceuticals, Inc. is 0%
The biggest institutional and mutual fund holders of Zynerba Pharmaceuticals, Inc. stock are
- Vanguard Group Inc
- Blackrock Inc.
- ETF Managers Group, LLC
- Renaissance Technologies, LLC
The Zynerba Pharmaceuticals, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0